Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Leukemia Research|January 1, 1990
Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotypeR L Momparler, N Onetto-Pothier, L F Momparler
Seminars in Oncology|August 1, 1993
Current dosage and schedule issues in the development of paclitaxel (Taxol)S G Arbuck, R Canetta, N Onetto, et al.
Leukemia Research|January 1, 1984
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylationR L Momparler, J Bouchard, N Onetto, et al.
Seminars in Oncology|December 1, 1992
Taxol: the first of the taxanes, an important new class of antitumor agentsE K Rowinsky, N Onetto, R M Canetta, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cellsR L Momparler, N Onetto-Pothier, D Y Bouffard, et al.
The Journal of Experimental Medicine|July 1, 1989
Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factorT Hoang, B Levy, N Onetto, et al.
Journal of Adolescent Health Care : Official Publication of the Society for Adolescent Medicine|December 1, 1983
Adolescents with chronic disease. Are they receiving comprehensive health care?G Carroll, E Massarelli, A Opzoomer, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Overview of Taxol safetyN Onetto, R Canetta, B Winograd, et al.
Investigational New Drugs|May 4, 2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancersK Gelmon, H Hirte, B Fisher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Pageof 3